As of November 4, 2026, Kyntra Bio, Inc. is a publicly traded company (Nasdaq: KYNB); its largest reported holder is Armistice Capital, with 9.88% on Schedule 13G/A of August 14, 2026. The largest insider holding is Christine Chung, the senior vice president and china operations, with 294,903 shares (7.3% of shares outstanding), per Form 4 of March 7, 2025 (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in Kyntra Bio, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Kyntra Bio, Inc. a real, registered company?
- Kyntra Bio, Inc. files with the SEC under CIK 921299 (its SEC filings).
- Its shares are listed under the ticker KYNB on Nasdaq (SEC company record).
- business address in San Francisco, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under KYNTRA BIO, INC. in our court records and SEC 8-K records (as of 2026-11-04).
- Leadership changes: the latest reported is Andrew E. Singer, Director (Form 8-K filed 2026-10-01). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Armistice Capital (filed 2026-08-14).
Who are Kyntra Bio, Inc.'s owners and officers?
Kyntra Bio, Inc.: business address in San Francisco, California; industry Pharmaceutical Preparations (Form D, 2026-10-01).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Armistice Capital, LLC | 9.88% |
| Schedule 13G/A, 2026-05-15 | Armistice Capital, LLC | 9.88% |
| Schedule 13G/A, 2026-02-17 | Armistice Capital, LLC | 9.89% |
| Schedule 13G/A, 2025-11-14 | Armistice Capital, LLC | 9.35% |
| Schedule 13G/A, 2025-08-15 | Armistice Capital, LLC | 8.31% |
| Schedule 13G/A, 2025-07-29 | The Vanguard Group | 4.4% |
Questions about who owns Kyntra Bio, Inc.
Who owns Kyntra Bio, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Kyntra Bio, Inc.: Armistice Capital, LLC (9.88%, Schedule 13G/A, filed 2026-08-14).
When did Armistice Capital, LLC buy into Kyntra Bio, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Armistice Capital, LLC on this page is the Schedule 13G/A, filed 2025-08-15, reporting 8.31%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.88%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Kyntra Bio, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Kyntra Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kyntra Bio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-10-01 | Andrew E. Singer | Director | appointed | 2026-10-01 |
Which insiders own Kyntra Bio, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the senior vice president and china operations: 294,903 shares (7.3% of shares outstanding) (Form 4, 2025-03-07).
- , the chief financial officer: 164,863 shares (4.1% of shares outstanding) (Form 4, 2024-12-09).
- , a director: 39,666 shares (0.98% of shares outstanding), held indirectly through a trust (Form 4, 2025-07-02).
- , the chief executive and a director: 26,836 shares (0.66% of shares outstanding), 26,796 held directly and 40 indirectly (Form 4, 2026-09-09).
- , the chief financial officer: 4,355 shares (0.11% of shares outstanding) (Form 4, 2026-09-09).
Shares outstanding: 4,049,124 as of 2026-07-31, from the company's latest SEC cover page.
How much has Kyntra Bio, Inc. raised?
No fundraising or offering filing from Kyntra Bio, Inc. is on file with us.
Keep reading
More on Kyntra Bio, Inc. and the records around it.
Kyntra Bio, Inc. elsewhere on the record
- Leadership changes Oct 2026
Companies that share a holder
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
- The Vanguard Group also filed stake reports on 2383 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/kyntra-bio